Financing channel feed – Endpoints News

Financing channel feed

Novartis backs eye drop maker in $20M round, meds to fill gap left by Eylea/Lucentis

8 years ago

BioNTech raises mammoth $270M A round, nearing $1B mark as investors continue a love affair with mRNA

8 years ago

Pfizer lines up an $830M alliance with Arvinas on protein degradation

8 years ago

All in: Boehringer Ingelheim more than doubles its venture fund to €250M

8 years ago

A better approach to growth factors? Scholar Rock raises $47M on SMA promise

8 years ago

Ex-Pfizer CEO's startup Centrexion gets $67M for PhIII painkiller

8 years ago

Celgene vet Barer lines up a $23M startup round for next-gen I/O tech out of Johns Hopkins

8 years ago

In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M

8 years ago

Following cancer combo deal with Bristol-Myers, Taris gets $25M Series B

8 years ago

Backed by Henri Termeer estate, Aura raises $30M for work to prevent blindness in eye cancer patients

8 years ago

In gene therapy's second big win this week, Orchard nabs $110M Series B

8 years ago

Flagship adds $618M in new funds to fuel startup mission

8 years ago

Parker Institute-allied Tessa grabs an $80M round for its next-gen cancer cell therapies

8 years ago

Bain leads big $70M round as Aptinyx plunges deeper into NMDA work

8 years ago

The 50 most active biotech VC funds in 2017

8 years ago

Jnana launches with $50M to spotlight an unexplored protein territory

8 years ago

Relay grabs $63M to pay for a drug discovery trip into the fourth dimension

8 years ago

Andreessen drums up a $450M fund to back their vision for engineering biology

8 years ago

Atlas and OrbiMed back Boston's Kyn in $49M round to pursue immunometabolism therapies

8 years ago

Yervoy inventor's oncology startup Pionyr gets $62M for tumor-fighting tech

8 years ago

Denali IPO hits a 2017 record $1.7B market valuation, raising $250M for neurodegeneration R&D

8 years ago

Sexual harassment in biotech hits home as OrbiMed’s Sam Isaly steps down in wake of STAT report

8 years ago

Rich Heyman's Metacrine grabs a $22M round in search of a superior NASH drug

8 years ago

Looking for the next big breakthrough in CAR-T, Mike Gilman debuts Obsidian with $49.5M round

8 years ago

First page Previous page 132 133 134135136 137 138 Next page Last page